Capital Area Research | Camp Hill, PA
Status and phase
Conditions
Treatments
About
The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-label extension during which they will receive up to 8 doses of ARO-ANG3.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: additional inclusion/exclusion criteria may apply per protocol
Primary purpose
Allocation
Interventional model
Masking
204 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal